Mast cells: The JEKYLL and HYDE of tumor growth

Trends in Immunology

Volumn 25, Issue 5, 2004, Pages 235-241

  Theoharides, Theoharis C ^a   Conti, Pio ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; HEPARIN; HISTAMINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MITOGENIC AGENT; NERVE GROWTH FACTOR; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; POLYAMINE; PROTEINASE; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

APOPTOSIS; BASAL CELL CARCINOMA; BREAST ADENOCARCINOMA; BREAST CANCER; ENDOTHELIUM CELL; GRANULE CELL; HUMAN; INFLAMMATION; MAST CELL; MELANOMA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NEUROFIBROMA; OXIDATION; POLARIZATION; REGULATORY MECHANISM; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH;

EID: 5644233966     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.02.013     Document Type: Article

References (71)

1. Mekori Y.A., et al. Mast cells in innate immunity. Immunol. Rev. 173:2000;131-140.
2. Redegeld F.A., et al. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol. 24:2003;181-185.
3. Pedotti R., et al. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 24:2003;479-484.
4. Almholt K., et al. Stromal cell involvement in cancer. Cancer Res. 162:2003;31-42.
5. Murphy P.M. Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345:2001;833-835.
6. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
7. Pollard, J.W. (2004) Tumour-educated macrophages promote tumour regression and....
8. Yu J.L., et al. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res. 5:2003;83-88.
9. Barbera-Guillem E., et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 62:2002;7042-7049.
10. Kataki A., et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 140:2002;320-328.
11. Egami K., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 112:2003;67-75.
12. Li C., et al. Infiltration of tumor-associated macrophages in human oral squamous cell carcinoma. Oncol. Rep. 9:2002;1219-1223.
13. Leek R.D., et al. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia. 7:2002;177-189.
14. Conti P., et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic mast cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood. 89:1997;4120-4127.
15. Molin D., et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br. J. Haematol. 119:2002;122-124.
16. Theoharides T.C. Neuroimmunology of tumor growth: the role of mast cells. Int. J. Immunopathol. Pharmacol. 1:1988;89-98.
17. Theoharides T.C., et al. Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. Science. 201:1978;1143-1145.
18. Theoharides T.C., et al. Differential release of serotonin and histamine from mast cells. Nature. 297:1982;229-231.
19. Sieghart W., et al. Calcium-dependent protein phosphorylation during secretion by exocytosis in the mast cell. Nature. 275:1978;329-331.
20. Theoharides T.C., et al. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science. 207:1980;80-82.
21. Theoharides T.C., et al. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 146:2004;1-12.
22. Ochi H., et al. IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10509-10513.
23. Gagari E., et al. Differential release of mast cell interleukin-6 via c-kit. Blood. 89:1997;2654-2663.
24. Theoharides T.C., et al. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J. Urol. 153:1995;629-636.
25. Claman H.N., et al. Mast cell 'disappearance' in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of 'phantom mast cells'. J. Immunol. 137:1986;2009-2013.
26. Frossi B., et al. Oxidative stress stimulates IL-4 and IL-6 production in mast cells by an APE/Ref-1-dependent pathway. Eur. J. Immunol. 33:2003;2168-2177.
27. Coleman J.W. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin. Exp. Immunol. 129:2002;4-10.
28. Vliagoftis H., et al. Inhibition of mast cell secretion by oxidation products of natural polyamines. Biochem. Pharmacol. 43:1992;2237-2245.
29. Boesiger J., et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcε reptor I expression. J. Exp. Med. 188:1998;1135-1145.
30. 206. Mol. Biol. Cell. 9:1998;875-884.
31. v mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer. 42:1988;48-52.
32. Niwa Y., et al. Anemia and mast cell depletion in mutant rats that are homozygous at 'white spotting (Ws)' locus. Blood. 78:1991;1936-1941.
33. Liu J.D., et al. Molecular mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Mol. Carcinog. 37:2003;39-50.
34. Lazar-Molnar E., et al. Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. Eur. J. Clin. Invest. 32:2002;743-749.
35. Nielsen H.J., et al. Ranitidine as adjuvant treatment in colorectal cancer. Br. J. Surg. 89:2002;1416-1422.
36. Parshad R., et al. Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. Acta Oncol. 41:2002;362-365.
37. Bowrey P.F., et al. Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br. J. Cancer. 82:2000;167-170.
38. Dabbous M.K., et al. Mast cells and matrix degradation at sites of tumor invasion in rat mammary adenocarinoma. Br. J. Cancer. 54:1986;459-465.
39. Esposito P., et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain barrier permeability induced by acute stress. J. Pharmacol. Exp. Ther. 303:2002;1061-1066.
40. Schouten L.J., et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 94:2002;2698-2705.
41. Salgado R., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer. 103:2003;642-646.
42. Letourneau R., et al. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. Br. J. Urol. 77:1996;41-54.
43. Kandere-Grzybowska K., et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J. Immunol. 171:2003;4830-4836.
44. Salven P., et al. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 16:2002;1471-1473.
45. Tsuji R.F., et al. Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon γ: a possible initiating role of B cells. J. Exp. Med. 186:1997;1015-1026.
46. D'Andrea M.R., et al. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am. J. Pathol. 158:2001;2031-2041.
47. Gooch J.L., et al. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res. 58:1998;4199-4205.
48. Gordon J.R., et al. Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin. Nature. 346:1990;274-276.
49. Fannon M., et al. Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J. 17:2003;902-904.
50. Su M.Y., et al. Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. Am. J. Pathol. 159:2001;245-251.
51. Samoszuk M., et al. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int. J. Cancer. 107:2003;159-163.
52. Hinrichs U., et al. Stromal accumulation of chondroitin sulphate in mammary tumours of dogs. Br. J. Cancer. 80:1999;1359-1365.
53. Kokenyesi R. Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. J. Cell. Biochem. 83:2001;259-270.
54. Strum J.M., et al. Structural alterations within N-nitrosomethylurea- induced mammary tumors after in vivo treatment with cis-hydroxyproline. Lab. Invest. 45:1981;347-354.
55. Andersson A.-C., et al. Diamines and polyamines in DMBA-induced breast carcinoma containing mast cells resistant to compound 48/80. Agents Actions. 6:1976;577-583.
56. Quan C., et al. Resistance to mammary carcinogenesis in Copenhagen rats: potential roles of vascular endothelial growth factor and mast cells. Cancer Lett. 186:2002;165-175.
57. Ohno S., et al. Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation? Anticancer Res. 22:2002;4269-4275.
58. Maffini, M.V. et al. The stroma as a crucial target in rat mammary gland carcinogenesis. J. Cell Sci. (in press).
59. Barcellos-Hoff M.H. The potential influence of radiation-induced microenvironments in neoplastic progression. J. Mammary Gland Biol. Neoplasia. 3:1998;165-175.
60. Sternlicht M.D., et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 98:1999;137-146.
61. Barcellos-Hoff M.H., et al. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:2000;1254-1260.
62. Arnold J.T., et al. Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture method. Hum. Reprod. 16:2001;836-845.
63. Grimbaldeston M.A., et al. Communications: high dermal mast cell prevalence is a predisposing factor for basal cell carcinoma in humans. J. Invest. Dermatol. 115:2000;317-320.
64. Reed J.A., et al. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. J. Cutan. Pathol. 23:1996;495-505.
65. Dvorak A.M., et al. Melanoma. An ultrastructural study of the host inflammatory and vascular responses. J. Invest. Dermatol. 75:1980;388-393.
66. Ryan J.J., et al. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J. Neurosci. Res. 37:1994;415-432.
67. Ingram D.A., et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med. 191:2000;181-188.
68. Claman H.L. New hope for neurofibromatosis? The mast cell connection. J. Am. Med. Assoc. 258:1987;823.
69. Zhu Y., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 296:2002;920-922.
70. Middleton E., et al. The effects of plant flavanoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev. 52:2000;673-761.
71. Theoharides, T.C. et al. Mast cells and mast cell mediators as targets of dietary supplements. Ann. Allergy, Asthma, Immunol. (in press).